$1.92
Live
Insights on Atai Life Sciences Nv
Revenue is down for the last 3 quarters, 172.0K → 18.0K (in $), with an average decrease of 64.4% per quarter
Netprofit is down for the last 2 quarters, 44.24M → -18.29M (in $), with an average decrease of 141.3% per quarter
In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 50.9%
3.91%
Downside
Day's Volatility :3.91%
Upside
0.0%
46.87%
Downside
52 Weeks Volatility :64.21%
Upside
32.63%
Period | Atai Life Sciences Nv | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 13.22% | 1.9% | 0.0% |
6 Months | 60.16% | 10.7% | 0.0% |
1 Year | 0.0% | 4.6% | -1.1% |
3 Years | -89.87% | 14.2% | -22.1% |
Market Capitalization | 310.5M |
Book Value | $1.46 |
Earnings Per Share (EPS) | -0.25 |
Wall Street Target Price | 10.68 |
Profit Margin | 0.0% |
Operating Margin TTM | -186483.33% |
Return On Assets TTM | -25.52% |
Return On Equity TTM | -17.21% |
Revenue TTM | 314.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -52.6% |
Gross Profit TTM | 233.0K |
EBITDA | -122.0M |
Diluted Eps TTM | -0.25 |
Quarterly Earnings Growth YOY | -0.97 |
EPS Estimate Current Year | -0.77 |
EPS Estimate Next Year | -0.77 |
EPS Estimate Current Quarter | -0.16 |
EPS Estimate Next Quarter | -0.17 |
What analysts predicted
Upside of 456.25%
Sell
Neutral
Buy
Atai Life Sciences Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Atai Life Sciences Nv | 18.67% | 60.16% | 0.0% | -89.87% | -89.87% |
Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
Vertex Pharmaceuticals Incorporated | -2.67% | 9.62% | 21.65% | 86.62% | 134.62% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Atai Life Sciences Nv | NA | NA | NA | -0.77 | -0.17 | -0.26 | NA | 1.46 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Atai Life Sciences Nv | Buy | $310.5M | -89.87% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 134.62% | 28.81 | 36.68% |
Morgan Stanley - Brokerage Accounts
BlackRock Inc
Marshall Wace Asset Management Ltd
Millennium Management LLC
Brown University
Mirae Asset Global Investments (Korea) Co Ltd
Atai Life Sciences Nv’s price-to-earnings ratio stands at None
Read Morewho we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.
Organization | Atai Life Sciences Nv |
Employees | 83 |
CEO | Mr. Christian Angermayer |
Industry | Commercial Services |